目的:探讨乌司他丁对脓毒性休克患儿的治疗效果。方法:将该院2010年10月~2012年10月间60例脓毒性休克患儿随机分为两组,治疗组30例及对照组30例,并选取20例健康体检者为正常组,治疗组在常规治疗基础上静滴乌司他丁,连用5天,治疗前及治疗后5天分别采外周血检测巨噬细胞移动抑制因子水平,并按小儿危重病例评分法(PCIS)进行评分。结果:治疗组与对照组治疗后的巨噬细胞移动抑制因子较治疗前均下降并有统计学意义,治疗组较对照组治疗后的巨噬细胞移动抑制因子下降更明显,有统计学意义。治疗组与对照组治疗后的PCIS评分较治疗前均升高并有统计学意义,治疗组较对照组的PCIS评分升高更明显,并有统计学意义。结论:乌司他丁能降低脓毒性休克患儿的炎症反应,阻断病情进一步恶化,值得推广。 Objective: To investigate the effect of ulinastatin on children with septic shock. Methods: Sixty children with septic shock in our hospital from October 2010 to October 2012 were randomly divided into two groups: 30 cases in the treatment group and 30 cases in the control group, and 20 healthy subjects were selected as the normal group. The patients were given ulinastatin intravenously on the basis of routine treatment. The levels of macrophage migration inhibitory factor (PBMC) in peripheral blood were measured before treatment and 5 days after treatment, and were scored according to the critical illness score of children (PCIS). Results: The migration inhibitory factor of macrophages in treatment group and control group decreased significantly compared with those before treatment, and the decrease of macrophage migration inhibitory factor in treatment group was more significant than that in control group after treatment. The PCIS score of the treatment group and the control group after treatment was significantly higher than that before treatment, and the PCIS score of the treatment group was significantly higher than that of the control group, with statistical significance. Conclusion: Ulinastatin can reduce the inflammatory reaction in children with septic shock and prevent the disease from deteriorating further. It is worth promoting.